BSPM - Biostar Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8200
0.0000 (0.0000%)
At close: 3:48PM EDT
Stock chart is not supported by your current browser
Previous Close2.8200
Open2.8000
Bid2.8000 x 200
Ask3.2000 x 500
Day's Range2.8000 - 2.9390
52 Week Range1.1800 - 5.9700
Volume14,706
Avg. Volume966,824
Market Cap7.437M
Beta0.92
PE Ratio (TTM)8.29
EPS (TTM)0.3400
Earnings DateApr 11, 2018 - Apr 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • Who Are The Major Shareholders Of Biostar Pharmaceuticals Inc (NASDAQ:BSPM)?
    Simply Wall St.11 days ago

    Who Are The Major Shareholders Of Biostar Pharmaceuticals Inc (NASDAQ:BSPM)?

    In this article, I’m going to take a look at Biostar Pharmaceuticals Inc’s (NASDAQ:BSPM) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Best Cheap Stocks To Buy
    Simply Wall St.last month

    Best Cheap Stocks To Buy

    Undervalued companies are those that trade at a price lower than their actual values, such as Park-Ohio Holdings and Nautilus. There’s a few ways you can value a company. TheRead More...

  • Is Biostar Pharmaceuticals Inc (NASDAQ:BSPM) A Financially Sound Company?
    Simply Wall St.last month

    Is Biostar Pharmaceuticals Inc (NASDAQ:BSPM) A Financially Sound Company?

    Biostar Pharmaceuticals Inc (NASDAQ:BSPM) is a small-cap stock with a market capitalization of US$8.94M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • PR Newswire2 months ago

    Biostar Pharmaceuticals, Inc. Announces Plans to Launch a New eCommerce Sales Platform

    XIANYANG, China, Feb. 21, 2018 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its plans to launch a new e-commerce sales platform (the "Sales Platform") following nearly ten months of research and preparation. The Company intends to complete this platform by the end of March 2018 and launch it during the second fiscal quarter of 2018. The Sales Platform will take a full advantage of various IT trends, including the latest trending content, sharing economy, innovative promotion of traditional and new e-commerce, Wechat business distribution system, etc. The Company will also include its B2C online shopping mall within the Sales Platform to promote its product line.

  • Best Undervalued Stock in February
    Simply Wall St.2 months ago

    Best Undervalued Stock in February

    Companies, such as Biostar Pharmaceuticals, are deemed to be undervalued because their shares are currently trading below their true values. Investors can profit from the difference by investing in theseRead More...

  • PR Newswire2 months ago

    Shaanxi Aoxing Pharmaceutical Co., Ltd. Renewed its GMP Certification

    XIANYANG, China, Feb. 7, 2018 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its variable interest entity in China, Shaanxi Aoxing Pharmaceutical Co., Ltd. ("Aoxing"), has renewed its Good Manufacturing Practices (GMP) certificate and Pharmaceutical Production License. The Company received the renewed GMP certificate evidencing compliance on January 31, 2018.

  • ACCESSWIRE3 months ago

    Biostar Pharma Post Huge Gains, Pipeline Review, and a New Product

    NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Why Biostar Pharmaceuticals Inc (NASDAQ:BSPM) May Not Be As Efficient As Its Industry
    Simply Wall St.3 months ago

    Why Biostar Pharmaceuticals Inc (NASDAQ:BSPM) May Not Be As Efficient As Its Industry

    Biostar Pharmaceuticals Inc’s (NASDAQ:BSPM) most recent return on equity was a substandard 2.66% relative to its industry performance of 11.58% over the past year. Though BSPM’s recent performance is underwhelming,Read More...

  • December Undervalued Opportunities – Biostar Pharmaceuticals And More
    Simply Wall St.4 months ago

    December Undervalued Opportunities – Biostar Pharmaceuticals And More

    Biostar Pharmaceuticals and Goodrich Petroleum are two of the stocks I have identified as undervalued. This means their current share prices are trading at levels less than what the companiesRead More...

  • PR Newswire5 months ago

    Biostar Regains Compliance with NASDAQ Continued Listing Requirement

    XIANYANG, China, Dec. 4, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced that on November 30, 2017, it received a letter from the NASDAQ Listing Qualifications Staff ("Staff") notifying the Company that it regained compliance with NASDAQ's Listing Rule 5250(c)(1) for continued listing on NASDAQ Capital Market and the Staff considers the matter closed. On August 22, 2017, the Company received a Staff notification letter advising the Company that, since it had not filed its Quarterly Report on Form 10-Q for the fiscal year ended June 30, 2017, the Company was not in compliance with NASDAQ Listing Rule 5250(c)(1).

  • Network-1 Technologies And Other Top Undervalued Stocks
    Simply Wall St.5 months ago

    Network-1 Technologies And Other Top Undervalued Stocks

    Network-1 Technologies and Goodrich Petroleum are two of the stocks I have identified as undervalued. This means their current share prices are trading at levels less than what the companiesRead More...

  • PR Newswire5 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Nine Months Ended September 30, 2017

    XIANYANG, China , Nov. 20, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and ...

  • PR Newswire5 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2017

    XIANYANG, China , Nov. 15, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and ...

  • Is Biostar Pharmaceuticals Inc’s (BSPM) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.6 months ago

    Is Biostar Pharmaceuticals Inc’s (BSPM) Balance Sheet Strong Enough To Weather A Storm?

    Investors are always looking for growth in small-cap stocks like Biostar Pharmaceuticals Inc (NASDAQ:BSPM), with a market cap of USD $4.37M. However, an important fact which most ignore is: howRead More...

  • ACCESSWIRE6 months ago

    3 Trending Biotech Stocks To Watch On Monday

    CORAL GABLES, FL / ACCESSWIRE / October 9, 2017 / Here are three trending biotech stocks to watch during Monday's trading session: GT Biopharma Inc. (GTBP) , a targeted immunotherapies company with near ...

  • PR Newswire8 months ago

    Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

    XIANYANG, China, Aug. 28, 2017 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on August 22, 2017 it received a notification letter from Nasdaq Listing Qualifications ("Nasdaq") advising the Company that, since it had not filed its Quarterly Report on Form 10-Q for the fiscal year ended June 30, 2017, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing. The Company is required within 60 calendar days of the Nasdaq notification to submit a plan of compliance with the foregoing continued listing deficiency. If the Company's plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days (or until February 12, 2018) to regain compliance.

  • PR Newswire11 months ago

    Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2017

    XIANYANG, China, May 19, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health ...